# CERTIFICATION

I, Paul Averback, certify
that:

|1. | I
have reviewed this annual report on Form 20-F of Nymox Pharmaceutical
               Corporation;
|-- | ---------------------------------------------------------------------------------------------------

|2. | Based
on my knowledge, this report does not contain any untrue statement of a
               material fact or omit to state a material fact necessary to make the
statements                made, in light of the circumstances under which such statements
were made, not                misleading with respect to the period covered by this
report;
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|3. | Based
on my knowledge, the financial statements, and other financial information
               included in this report, fairly present in all material respects the
financial                condition, results of operations and cash flows of the company
as of, and for,                the periods presented in this report;
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|4. | The
companys other certifying officers and I are responsible for
               establishing and maintaining disclosure controls and procedures (as
defined in                Exchange Act Rules 13a  15(e) and 15d  15(e)) for
the company and we                have:
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | a)
                     designed such disclosure controls and procedures, or caused such
disclosure                     controls and  procedures to be designed under our
supervision, to ensure                     that material information relating to the
company, including its consolidated                     subsidiaries, is made known to us
by others within those entities, particularly                     during the period in
which this report is being prepared;
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | b)
                     evaluated the effectiveness of the companys disclosure
controls and                     procedures and presented in this report our conclusions
about the effectiveness                     of the disclosures and procedures, as of the
end of the period covered by this                     report based on such evaluation;
and
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | c)
                     disclosed in this report any change in the companys internal
control over                     financial reporting that occurred during the period
covered by the annual report                     that has materially affected, or is
reasonably likely to materially affect, the                     companys internal
control over financial reporting; and
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|5. | The
companys other certifying officer(s) and I have disclosed, based on
               our most recent evaluation of internal control over financial reporting,
to the                companys auditors and the audit committee of companys
board of                directors (or persons performing the equivalent function):
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | a)
                     All significant deficiencies and material weaknesses in the design
or operation                     of internal control over financial reporting which are
reasonably likely to                     adversely affect the companys ability to
record, process, summarize and                     report financial information; and
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | b)
                     Any fraud, whether or not material, that involves management or
other employees                     who have a significant role in the companys
internal control over                     financial reporting.
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: June 26, 2007

| | /s/
Paul Averback, MD Paul Averback, MDPresident and Chief Executive OfficerNymox
Pharmaceutical Corporation
| | ------------------------------------------------------------------------------------------------------------